Skip to search formSkip to main contentSkip to account menu

flosequinan

Known as: 7-fluoro-1-methyl-3-methylsulfinyl-4-quinoline, flosequinan [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

BTS 49465

Broader (2)

QuinolinesVasodilator Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Negative, neutral, and discordant results: what should an editor do?
This issue of the Journal of Cardiac Failure includes a manuscript examining the prognosis of a large cohort of hospitalized… 
2003
2003
Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance
Flosequinan (manoplax) is a new vasodilating agent for the treatment of congestive heart failure. Although it may have several… 
2001
2001
Positive Inotropes—A New Horizon or Still a Dead End?
Currently available guidelines on the treatment of heart failure clearly indicate the limitations of available inotropic therapy… 
1998
1998
Pharmacokinetics of Flosequinan and its Sulphone Metabolite in Asian Indians
The pharmacokinetics of flosequinan, a peripheral vasodilator, and its active sulphone metabolite, flosequinoxan, were… 
1994
1994
Assessment of Flosequinan's Direct Effect on Human Arterial, Venous, and Cardiac Muscle: Comparison with Other Classes of Agents Used to Treat Heart Failure
Summary: We wished to provide comparative information regarding the direct effects of flosequinan, a novel quinolone under… 
Review
1993
Review
1993
▾ Flosequinan for chronic heart failure?
Flosequinan (Manoplax – Boots), an arteriolar- and veno-dilator, is licensed in the UK for the treatment of patients with chronic… 
1993
1993
Heart failure: drug therapy in the nineties and beyond.
: The lesson learned from recent advances in the understanding of congestive heart failure is that it is too complex a process to… 
1990
1990
Exercise capacity, hemodynamic, and neurohumoral changes following acute and chronic administration of flosequinan in chronic congestive heart failure
SummaryWe evaluated the responses to 90 minutes and 8 days of therapy with a new long-acting vasodilator flosequinan in ten… 
1989
1989
Positive Inotropic and Hemodynamic Properties of Flosequinan, a New Vasodilator, and a Sulfone Metabolite
Flosequinan, a new orally active vasodilator, and its sulfone metabolite were evaluated for inotropic activity in isolated ferret… 
1989
1989
Effect of flosequinan on ambulatory blood pressure and renal hemodynamics in essential hypertension